SCHEMBL19793345

SCHEMBL19793345

Cc1ccc2cc(C)oc(=O)c2c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.53
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
MAOA P21397 1/20 0.43
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
PTK2B Q14289 1/20 0.42
C1R P00736 1/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2A6 P11509 3/20 0.41
ANTXR2 P58335 1/20 0.41
NQO1 P15559 1/20 0.40
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27845272 0.84 ELANE (0.49) ELANEALDH1A1KDM4ELMNAMAPT
SCHEMBL12958021 0.81 ELANE (0.50) ELANEALDH1A1KDM4ELMNAMAPT
SCHEMBL19793344 0.78 KDM4E (0.54) ALDH1A1KDM4ELMNAMAPTPOLB
SCHEMBL295233 0.78 PTGES (0.56) ELANEALDH1A1KDM4EMAPTMAOA
SCHEMBL31604207 0.78 PTGES (0.56) ELANEALDH1A1KDM4EMAPTMAOA
SCHEMBL28923758 0.77 ELANE (0.46) ELANEALDH1A1KDM4ELMNAMAPT
SCHEMBL9104680 0.77 GRIN2D (0.44) ALDH1A1KDM4EMAPTMAOAMEN1
SCHEMBL28325016 0.77 MAOA (0.38) ELANEALDH1A1KDM4ELMNAMAPT
SCHEMBL14985665 0.74 ELANE (0.47) ELANEALDH1A1KDM4ELMNAMAPT
SCHEMBL9103336 0.74 HIPK2 (0.42) ALDH1A1LMNAMAOAANTXR2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10428273-B2 Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2019-10-01 US disclosed
US-20180022998-A1 LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-01-25 US disclosed
US-20180022998-A1 LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428273-B2 Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device PIEZO1, PYCARD, NLRP1 ELANE 2653/4885ALDH1A1 2282/4885KDM4E 2394/4885
US-20180022998-A1 LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE PIEZO1, NLRP1, PYCARD ELANE 2588/4885ALDH1A1 2304/4885KDM4E 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.